TNF Pharmaceuticals Plunges 16.13% on Reverse Stock Split

Generated by AI AgentAinvest Pre-Market Radar
Friday, Aug 29, 2025 4:31 am ET1min read
Aime RobotAime Summary

- TNF Pharmaceuticals' stock plunged 16.13% pre-market after announcing a 100:1 reverse stock split to meet Nasdaq listing requirements.

- The split, effective September 2, reduces shares from 178.6M to 1.786M to avoid delisting risks due to low stock prices.

- The board aims to boost share price by consolidating shares, addressing governance concerns amid the significant pre-market decline.

On August 29, 2025,

experienced a significant drop of 16.13% in pre-market trading, marking a notable decline in its stock performance.

TNF Pharmaceuticals has announced a reverse stock split, which will reduce the number of outstanding shares from 178,615,658 to 1,786,157. This move is aimed at meeting Nasdaq listing requirements and improving the company's share price. The split will take effect on September 2, 2025, with a ratio of 1 post-split share for every 100 pre-split shares. This strategic decision by the board of directors is intended to address the risk of delisting from the Nasdaq due to a low stock price.

Comments



Add a public comment...
No comments

No comments yet